Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press105710.17650/1726-9776-2008-4-4-82-87REVIEWОБЗОРAngiogenic factors in renal cell carcinomaАнгиогенные факторы при почечно-клеточном ракеTrapeznikovaM. F.ТрапезниковаМ. Ф.Russian Federation
МОНИКИ им. М.Ф. ВладимирскогоГУ РОНЦ им. Н.Н. Блохина РАМНГУ РОНЦ им. Н.Н. Блохина РАМНМОНИКИ им. М.Ф. Владимирского301220084482871402202014022020https://oncourology.abvpress.ru/oncur/article/view/1057
.
.
1. Noden D.M. Embryonic origins and assembly of blood vessels. Am Rev Respir Dis 1989;140(4):1097—103.Noden D.M. Embryonic origins and assembly of blood vessels. Am Rev Respir Dis 1989;140(4):1097—103.2. Furcht L.T. Critical factors controlling angiogenesis: cell products, cell matrix, and growth factors. Lab Invest 1986;55(5):505—9.Furcht L.T. Critical factors controlling angiogenesis: cell products, cell matrix, and growth factors. Lab Invest 1986;55(5):505—9.3. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest 1995;99(3):373—6.Bischoff J. Cell adhesion and angiogenesis. J Clin Invest 1995;99(3):373—6.4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1(1):27—31.Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1(1):27—31.5. Folkman J. Antiangiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175(3):409—16.Folkman J. Antiangiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175(3):409—16.6. Folkman J., Klagsburn M. Angiogenic factors. Science 1987;235:442—7.Folkman J., Klagsburn M. Angiogenic factors. Science 1987;235:442—7.7. Papetti M., Herman I.M. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002;282(5): 947—70.Papetti M., Herman I.M. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002;282(5): 947—70.8. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 2002;94(12):883—93.Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 2002;94(12):883—93.9. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401—10.Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401—10.10. Dor Y., Porat R., Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 2001;280(6):1367—74.Dor Y., Porat R., Keshet E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 2001;280(6):1367—74.11. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368—80.Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368—80.12. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669—76.Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669—76.13. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36(2):127—37.Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36(2):127—37.14. Ferrara N., Keyt B. Vascular endothelial growth factor: basic biology and clinical implications. EXS 1997;79:209—32.Ferrara N., Keyt B. Vascular endothelial growth factor: basic biology and clinical implications. EXS 1997;79:209—32.15. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4—25.Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4—25.16. Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028—43.Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23:1028—43.17. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389—95.Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389—95.18. Holash J., Maisonpierre P.C., Compton D. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994—8.Holash J., Maisonpierre P.C., Compton D. et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994—8.19. Hirschi K.K., D’Amore P.A. Pericytes in the microvasculature. Cardiovasc Res 1996;32:687—98.Hirschi K.K., D’Amore P.A. Pericytes in the microvasculature. Cardiovasc Res 1996;32:687—98.20. Benjamin L.E., Hemo I., Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125:1591—8.Benjamin L.E., Hemo I., Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998;125:1591—8.21. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650—9.Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650—9.22. Benjamin L.E., Golijanin D., Itin A. et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159—65.Benjamin L.E., Golijanin D., Itin A. et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999;103:159—65.23. Morikawa S., Baluk P., Kaidoh T. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985—1000.Morikawa S., Baluk P., Kaidoh T. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985—1000.24. Benjamin L.E., Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94:8761—6.Benjamin L.E., Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 1997;94:8761—6.25. Rafii S., Heissig B., Hattori K. Efficient mobilization and recruitment of marrowderived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther 2002;9:631—41.Rafii S., Heissig B., Hattori K. Efficient mobilization and recruitment of marrowderived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther 2002;9:631—41.26. Hattori K., Dias S., Heissig B. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001;193:1005—14.Hattori K., Dias S., Heissig B. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001;193:1005—14.27. Hattori K., Heissig B., Wu Y. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002;8:841—9.Hattori K., Heissig B., Wu Y. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002;8:841—9.28. Pettersson A., Nagy J.A., Brown L.F. et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000;80:99—115.Pettersson A., Nagy J.A., Brown L.F. et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000;80:99—115.29. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62—S67.Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62—S67.30. Maxwell P.H., Pugh C.W., Ratcliffe P.J. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001;11:293—9.Maxwell P.H., Pugh C.W., Ratcliffe P.J. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001;11:293—9.31. Black W.C., Welch H.G. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993:328:1237—43.Black W.C., Welch H.G. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993:328:1237—43.32. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev Cancer 2002;2:727—39.Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nature Rev Cancer 2002;2:727—39.33. Igarashi H., Esumi M., Ishida H. et al. Vascular endothelial growth factor overexpression is correlated with von HippelLindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 2002;95(1):47—53.Igarashi H., Esumi M., Ishida H. et al. Vascular endothelial growth factor overexpression is correlated with von HippelLindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 2002;95(1):47—53.34. Zhang X., Yamashita M., Uetsuki H. et al. Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. Int J Urol 2002;9(Issue 9):509—14.Zhang X., Yamashita M., Uetsuki H. et al. Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. Int J Urol 2002;9(Issue 9):509—14.35. Djordjevic G., Mozetic V., Mozetic D.V. et al. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract 2007;203(2):99—106.Djordjevic G., Mozetic V., Mozetic D.V. et al. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract 2007;203(2):99—106.36. Raica M., Cimpean A.M., Anghel A. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma. Neoplasma 2007;54(4):278—84.Raica M., Cimpean A.M., Anghel A. Immunohistochemical expression of vascular endothelial growth factor (VEGF) does not correlate with microvessel density in renal cell carcinoma. Neoplasma 2007;54(4):278—84.37. Baldewijns M.M., Thijssen V.L., Van den Eynden G.G. et al. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer 2007;96(12):1888—95.Baldewijns M.M., Thijssen V.L., Van den Eynden G.G. et al. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer 2007;96(12):1888—95.38. Paradis V., Lagha N.B., Zeimoura L. et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 2000;436:351—6.Paradis V., Lagha N.B., Zeimoura L. et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 2000;436:351—6.39. Jacobsen J., Grankvist K., Rasmuson T. et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004;93:297—302.Jacobsen J., Grankvist K., Rasmuson T. et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004;93:297—302.40. Jacobsen J., Grankvist K., Rasmuson T. et al. Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. BJU Int 2006;97(5):1102—108.Jacobsen J., Grankvist K., Rasmuson T. et al. Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. BJU Int 2006;97(5):1102—108.41. Ljungberg B., Jacobsen J., Häggström-Rudolfssson S. et al. Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urol Res 2003;31(5):335—40.Ljungberg B., Jacobsen J., Häggström-Rudolfssson S. et al. Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma. Urol Res 2003;31(5):335—40.42. Rivet J., Mourah S., Murata H. et al. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer 2008;112(2):433—42.Rivet J., Mourah S., Murata H. et al. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer 2008;112(2):433—42.43. Minardi D., Lucarini G., Mazzucchelli R. et al. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J Urology 2005;174(Issue 4):1208—12.Minardi D., Lucarini G., Mazzucchelli R. et al. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J Urology 2005;174(Issue 4):1208—12.44. Sato K., Tsuchiya N., Sasaki R. et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 1999;90(8):874—9.Sato K., Tsuchiya N., Sasaki R. et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 1999;90(8):874—9.45. Jacobsen J., Rasmuson T., Grankvist K. et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163(1):343—7.Jacobsen J., Rasmuson T., Grankvist K. et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163(1):343—7.46. Alamdari F.I., Rasmuson T., Grankvist K. et al. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. Scand J Urol Nephrol 2007;41(1):5—9.Alamdari F.I., Rasmuson T., Grankvist K. et al. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. Scand J Urol Nephrol 2007;41(1):5—9.47. Schips L., Dalpiaz O., Lipsky K. et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur J Urol 2007;51(1):168—73.Schips L., Dalpiaz O., Lipsky K. et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur J Urol 2007;51(1):168—73.